BSE - Delayed Quote INR

Divi's Laboratories Limited (DIVISLAB.BO)

6,001.10
+42.75
+(0.72%)
At close: May 9 at 3:29:00 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
90,290,000
77,960,000
76,650,000
87,992,300
68,583,400
Cost of Revenue
37,860,000
32,690,000
31,780,000
30,918,800
24,326,700
Gross Profit
52,430,000
45,270,000
44,870,000
57,073,500
44,256,700
Operating Expense
28,130,000
26,950,000
24,600,000
21,335,800
18,096,800
Operating Income
24,300,000
18,320,000
20,270,000
35,737,700
26,159,900
Net Non Operating Interest Income Expense
2,970,000
2,970,000
2,030,000
669,600
551,400
Pretax Income
27,650,000
21,630,000
23,690,000
36,835,000
26,660,400
Tax Provision
6,980,000
5,630,000
5,450,000
7,230,500
6,817,500
Net Income Common Stockholders
20,670,000
16,000,000
18,240,000
29,604,500
19,842,900
Diluted NI Available to Com Stockholders
20,670,000
16,000,000
18,240,000
29,604,500
19,842,900
Basic EPS
77.85
60.27
68.69
111.52
74.75
Diluted EPS
77.85
60.27
68.69
111.52
74.75
Basic Average Shares
265,531.63
265,468.58
265,468.58
265,468.58
265,468.58
Diluted Average Shares
265,531.63
265,468.58
265,468.58
265,468.58
265,468.58
Rent Expense Supplemental
--
120,000
120,000
107,700
108,600
Total Expenses
65,990,000
59,640,000
56,380,000
52,254,600
42,423,500
Net Income from Continuing & Discontinued Operation
20,670,000
16,000,000
18,240,000
29,604,500
19,842,900
Normalized Income
20,662,524.41
15,992,602.87
18,209,202.20
29,620,975.97
19,867,535.79
Interest Income
--
3,010,000
2,050,000
689,600
572,400
Interest Expense
30,000
30,000
0
3,700
3,900
Net Interest Income
2,970,000
2,970,000
2,030,000
669,600
551,400
EBIT
27,680,000
21,660,000
23,690,000
36,838,700
26,664,300
EBITDA
31,580,000
25,440,000
27,120,000
39,953,800
29,220,200
Reconciled Cost of Revenue
37,860,000
32,690,000
31,780,000
30,918,800
24,326,700
Reconciled Depreciation
3,900,000
3,780,000
3,430,000
3,115,100
2,555,900
Net Income from Continuing Operation Net Minority Interest
20,670,000
16,000,000
18,240,000
29,604,500
19,842,900
Total Unusual Items Excluding Goodwill
10,000
10,000
40,000
-20,500
-33,100
Total Unusual Items
10,000
10,000
40,000
-20,500
-33,100
Normalized EBITDA
31,570,000
25,430,000
27,080,000
39,974,300
29,253,300
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2,524.41
2,602.87
9,202.20
-4,024.03
-8,464.21
3/31/2021 - 3/25/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALKEM.NS Alkem Laboratories Limited
4,946.50
+0.14%
 
PPLPHARMA.BO Piramal Pharma Limited
207.90
+0.92%
 
ABBOTINDIA.BO Abbott India Limited
30,147.65
+0.42%
 
CIPLA.BO Cipla Limited
1,478.50
-0.55%
 
NATCOPHARM.BO NATCO Pharma Limited
809.55
+0.82%
 
ABBOTINDIA.NS Abbott India Limited
30,165.00
+0.53%
 
CAPLIPOINT.NS Caplin Point Laboratories Limited
1,860.90
-2.15%
 
DRREDDY.BO Dr. Reddy's Laboratories Limited
1,156.40
+0.67%
 
MANKIND.NS Mankind Pharma Limited
2,408.20
-1.28%
 
AUROPHARMA.NS Aurobindo Pharma Limited
1,164.40
+0.59%